Your browser doesn't support javascript.
loading
Heartware ventricular assist device versus HeartMate II versus HeartMate III in advanced heart failure patients: A systematic review and meta-analysis.
Hanafy, Dudy Arman; Husen, Theresia Feline; Angelica, Ruth; Nathania, Ilona; Trianita Suwatri, Widya; Lintangella, Pasati; Erdianto, Wahyu Prima; Prasetyo, Prisillia.
Afiliación
  • Hanafy DA; Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
  • Husen TF; Division of Adult Cardiac Surgery, Department of Surgery, National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia.
  • Angelica R; Faculty of Medicine, University of Indonesia, Pondok Cina, Beji, Depok City, West Java, Indonesia.
  • Nathania I; Faculty of Medicine, University of Indonesia, Pondok Cina, Beji, Depok City, West Java, Indonesia.
  • Trianita Suwatri W; Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
  • Lintangella P; Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
  • Erdianto WP; Division of Adult Cardiac Surgery, Department of Surgery, National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia.
  • Prasetyo P; Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
SAGE Open Med ; 12: 20503121241278226, 2024.
Article en En | MEDLINE | ID: mdl-39224898
ABSTRACT

Objective:

Ventricular assist device is one of the treatment options for heart failure patients. Therefore, the purpose of this review is to aid in clinical decision-making of exchanging previous older ventricular assist device models to the newest one, HM3.

Methods:

The search was conducted across several databases until February 25, 2023, and was registered with the ID of CRD42023405367. Risk of bias was performed using Cochrane Risk of Bias 2.0 and the Newcastle Ottawa Scale. In order to rank and evaluate the pooled odds ratios and mean differences with 95% confidence intervals, we employed conventional and Bayesian network meta-analysis converted to surface under the cumulative ranking.

Results:

A total of 49 studies with 31,105 patients were included in this review. HM3 is the best device exchange choice that causes the lowest risk of mortality (HM3 (99.98) > HM2 (32.43) > HVAD (17.58)), cerebrovascular accidents (HM3 (99.99) > HM2 (42.41) > HVAD (7.60)), other neurologic events beside cerebrovascular accident (HM3 (91.45) > HM2 (54.16) > HVAD (4.39)), pump thrombosis (HM3 (100.00) > HM2 (39.20) > HVAD (10.80)), and bleeding (HM3 (97.12) > HM2 (47.60) > HVAD (5.28)). HM3 is also better than HM2 in hospital admissions (OR 1.90 (95% CI 1.15-3.12)). When complications were present, HM2 or Heartware ventricular assist devices exchange to HM3 lowered the mortality rate compared to exchanging it to the same device type.

Conclusion:

HM3 is the best device for all six outcomes. Exchange from Heartware ventricular assist devices or HM2 to HM3 rather than the same ventricular assist device type is recommended only if a complication is present.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: SAGE Open Med Año: 2024 Tipo del documento: Article País de afiliación: Indonesia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: SAGE Open Med Año: 2024 Tipo del documento: Article País de afiliación: Indonesia Pais de publicación: Reino Unido